Dogs Double Risk for Distracted Driving

teen texting and driving-resized-600Distracted driving is something we usually associate with teens and their cell phones, or frenzied mothers and their minivan full of kids.  However the National Highway Safety Traffic Administration defines it as “anything that could potentially remove a driver’s eyes from the road, their hands from the steering wheel or their concentration from the task of driving.”

And that includes pets…

While most states have enacted legislation to curb the use of cell phones while driving, only one – Hawaii – has laws that specifically restrict drivers from having a pet in their lap. But a new study could be about to change all that.  The University of Alabama at Birmingham, research enrolled 2,000 drivers age 70 and older, of whom 691 had pets. Participants took a survey on driving habits, and those with pets were asked about the frequency of driving with pets. They also underwent visual sensory and higher-order visual processing testing.

driving-with-dogsThe results showed that senior drivers who take a pet in the car are at increased risk for being involved in a motor vehicle collision. Both overall, and at-fault, crash rates for drivers 70 years or older were higher for those whose pet habitually rode with them.

More than half the pet owners said they took their pet with them in the car at least occasionally, usually riding on the front passenger seat or in the back seat.

That is consistent with previous studies looking at all drivers, which indicate that slightly more than half of all drivers take a pet with them at times,” said Gerald McGwin, PhD, senior author of the study. “And it’s interesting to note that earlier surveys indicate that 83% of those surveyed agreed that an unrestrained dog was likely dangerous in a moving vehicle, yet only 16% have ever used any type of restraint on their own pet.”

The crash risk for drivers who always drove with their pets was double that of drivers who never drove with a pet, while crash rates for those who sometimes or rarely drove with pets were consistent with the rates for non-pet owners.

This is the first study to evaluate the presence of pets in a vehicle as a potential internal distraction for elderly drivers,” said McGwin. “The increased crash rate for elderly drivers who always drive with pets is important in the context of increasing driver awareness about potentially dangerous driving habits. There is no direct evidence that driving with pets is or is not a threat to public safety, however, indirect evidence exists based on distracted driving research on texting, eating or interacting with electronics or even other passengers and there are certainly anecdotal reports in the news media of crashes and even fatalities caused by drivers distracted by a pet in the vehicle.”

dog in carThe authors suggest that when confronted with an increased cognitive or physical workload while driving, elderly drivers have exhibited slower cognitive performance and delayed response times in comparison to younger age groups. Adding another distracting element, especially an animal, provides more opportunity for an older driver to respond to a driving situation in a less than satisfactory way.

Given the current debate about all types of distracted driving, further study of pet-related distracted driving behaviors among drivers, is warranted to appropriately inform the need for policy regulation on this issue.

Do you have thoughts on driving with pets?  Please let us know.

SRxA-logo for web

About these ads

Radioactive Bacteria:1 – Pancreatic Cancer:0

pancreatic cancer facesYears ago, when I was just starting my healthcare career, I worked with a team specializing in the management of patients with pancreatic cancer.  Despite the dedication and compassion of our team, revolutionary surgical techniques, and top-notch palliative care, all too often our patients died. Even today, some 30 years later, pancreatic cancer has a poor prognosis. It’s seldom detected in its early stages, and often spreads rapidly. Signs and symptoms frequently don’t appear until the disease is advanced and surgical removal isn’t possible.

Pancreatic cancer touches so many people. It killed my childhood mentor and one of my best friends. It’s taken the lives of many household names, from astronauts to actors, entrepreneurs to opera singers.  For example, Patrick Swayze, Randy Pausch, Luciano Pavarotti, Dizzy Gillespie, Count Basie, Michael Landon, Joan Crawford, Sally Ride and of course, Apple CEO – Steve Jobs.

So, I was excited to hear about new research into a targeted anti-cancer therapy that promised limited side effects. The study, published April 22 in the Proceedings of the National Academy of Sciences found that treating mice with an attenuated, radioactively labeled bacteria –  Listeria monocytogenes - drastically reduced the number of metastases, while leaving normal tissue unscathed.

The notion of using bacteria to attack tumors is not new. Robert Hoffman, a cancer biologist at the University of California, San Diego, who was not involved in the current study, has shown that Salmonella can kill mouse cancer cells, including metastases of pancreatic cancer.

Other research has shown that a Listeria strain known as CRS-207 has the ability to stimulate an immune response in Phase 1 and 2 trials.

listeria.monocytogenesIn the new study, researchers at Albert Einstein College of Medicine have paired this technique with a radioactive isotope to selectively kill tumor cells, focusing on the metastatic cells that so often elude current treatment regimens.

It’s this combination of approaches that synergistically target metastases, that’s new. Claudia Gravekamp, an immunologist at Albert Einstein College of Medicine who led the study with nuclear medicine researcher Ekaterina Dadachova had previously demonstrated that an attenuated strain of Listeria monocytogenes, a type of bacterium that penetrates host cells during infection, selectively killed breast cancer cells without damaging normal tissue. The bacteria’s ability to target only diseased cells raised the possibility that it could be used to treat metastatic cancer by both directly killing cells and by carrying anti-tumor therapies—like radiation—to cancer cells.

pancreatic_cancerGravekamp and Dadachova tested the bacteria against highly metastatic pancreatic cancer in mice. First, they demonstrated that the bacteria proliferated well in the animals’ metastases, but poorly in the primary tumor, and not at all in normal tissues like spleen, suggesting the bacteria would be good candidates for delivering a therapy to far-flung metastases.

Then, the researchers armed the Listeria with the Rhenium-188, a radionuclide that kills cells by releasing DNA-damaging. Sure enough, regular injections of the Rhenium-188 labeled bacteria decreased metastases by 90% versus controls.

While this implies that bacteria have to potential to be used to deliver therapeutic radiation doses to metastases, the bacteria were administered before metastases were established, notes Donald Buchsbaum, a radiation biologist at the University of Alabama at Birmingham who was not involved in the study.  “So to some extent it’s a prevention model.”

Future work will need to focus on targeting established metastases, possibly by exploring other radioisotope options.  Gravekamp and Dadachova are currently refining their protocol and examining alternative radioisotopes to achieve a 100% reduction of metastases, but have high hopes for their bacteria.

Though primary tumors are often removed surgically, even small pieces left behind can produce new metastases. It might be possible that one day radioactive Listeria could be part of an “early second-line treatment after surgery to prevent further metastases,” says Gravekamp.

ListeriaWhich is great news in the war against cancer and not a bad deal for the Listeria bacteria which normally gets a bad rap for causing the infection listeriosis  – the leading cause of death among food-borne bacterial pathogens – responsible for approximately 2,500 illnesses and 500 fatalities annually in the United States.

Exciting stuff!

SRxA-logo for web

Pumped Up about Promising new Parkinson’s Pump

parkinson-disease60Parkinson’s disease, as many of our readers know is a chronic, progressive neurological disease that causes sufferers to lose control of body movements, resulting in tremors, muscle stiffness, loss of balance and a host of other problems. Currently, there is no cure for Parkinson’s disease and treatment options are limited. Therapy is directed at treating the symptoms that are most bothersome and for this reason, there is no standard or “best” treatment for that applies to every patient.

Treatment approaches include medications and surgery (deep brain stimulation) as well as general lifestyle modifications (rest and exercise), physical, occupational and speech therapy.

levodopaAmong the drug-related therapies, levodopa is considered one of the most effective for relieving the symptoms of Parkinson’s disease. It helps reduce tremor, stiffness, and slowness and helps improve muscle control, balance, and walking. Levodopa does not slow the disease process, but it improves muscle movement and delays severe disability. So far, levodopa, which had been used to treat Parkinson’s since the 1970’s, has only been available in pill form.

But a new Cleveland Clinic study finds that using a pump to administer a gel form of levodopa directly into the small intestine is much more effective.

Neurologist Hubert Fernandez, MD, who led the study, says, “The levodopa pump decreased or improved what we call the ‘bad time’ in Parkinson’s patients by up to four hours per day.” The levodopa can control this ‘bad time’ — the tremors, muscle spasms and other movement disorders that makes it difficult for Parkinson’s patients to function on a daily basis.

parkinsons-gel-drug-pump-190x155This is an amazing finding,” says Fernandez. “We know of no other oral therapy that will improve the bad time in Parkinson’s by an average of four hours daily.”

The levodopa pump is external. It sits in a pouch under the patient’s shirt and provides a steady dose of the drug. The levodopa gel is administered directly into the small intestine, where most of the drug is absorbed. The constant dose makes the body’s movements more controlled and predictable, making it easier for people with the disease to plan and go about their day without worrying that the drug’s effects will wear off.

The biggest advantage of the levodopa is its efficacy,” Dr. Fernandez says. “We’re trying to deliver it on a continuous basis so the patients don’t need to take it every hour.” parkinsons gel pump

69-year-old Bob Van Housen has been living with Parkinson’s disease for over 12 years.  Prior to enrollment in the study he was having to take up to five levodopa pills every three hours to control his symptoms. Even then, his symptoms progressed to the point where it was hard to keep up.  “He was ‘off’ for at least seven hours,” said Van Housen’s wife, Carol. “Seven hours is a long time to not be able to function every day.”

The couple often had to cut their trips together short and limit their social outings outside of the house. Van Housen says that being part of the trial at Cleveland Clinic has been life-changing. “We can predict better how I’m going to feel and how I’m going to act and can plan trips and work around those times when I otherwise would have been problematic.”

The gel pump which is not yet available in the United States is currently under review by the Food and Drug Administration. Let’s hope it doesn’t hit any hurdles along the way, so others with Parkinson’s can avoid the roller-coaster of symptoms and enjoy the type of benefits that Bob has experienced.

SRxA-logo for web

Put on the red light

asleep-at-deskWe’ve all been there, some of us more often than others. You know what I’m talking about. That mid-afternoon moment where we find ourselves crashing at our computers. Or nodding off into our notebooks.

And it’s not just our productivity that’s affected.  It turns out that acute or chronic sleep deprivation and the resulting fatigue is one of the leading causes of workplace incidents and related injuries. Most performance failures, including car accidents, occur in the mid-afternoon hours known as the “post-lunch dip.”  Typically this occurs sometime between 2-4 p.m., or about 16-18 hours after the previous night’s bedtime.

Now a new study from the Lighting Research Center [who knew there was such a thing?]  at Rensselaer Polytechnic Institute – the nation’s oldest technological university - suggests that there may be a way to alleviate afternoon accidents.  Their research shows that exposure to certain wavelengths and levels of light have the potential to increase alertness during the post-lunch dip. These results pave the way for a non-pharmacological intervention to increase alertness during the daytime.

Mariana Figueiro, LRC Light and Health Program director, has previously conducted studies that show that light has the potential to increase alertness at night. Exposure to strong levels of white light at night increases performance, elevates core body temperature, and increases heart rate.

light-therapy2In most studies to date, the alerting effects of light have been linked to its ability to suppress the circadian rhythm regulating hormone – melatonin, the levels of which are typically lower during the daytime, and higher at night. However, results from a previous study by Figueiro demonstrated that acute melatonin suppression is not needed for light to affect alertness during the nighttime. While both short-wavelength (blue) and long-wavelength (red) lights increased measures of alertness, only short-wavelength light suppressed melatonin.

Based on this finding the researchers hypothesized that if light can impact alertness via pathways other than melatonin suppression, then certain wavelengths and levels of light might also increase alertness during the middle of the afternoon.

During the study, participants experienced two experimental lighting conditions in addition to darkness. Long-wavelength “red” light and short-wavelength “blue” light were delivered to the corneas of each participant by arrays of light emitting diodes (LEDs) placed in light boxes. Participant alertness was measured by electroencephalogram (EEG) and subjective sleepiness (KSS scale).

The team found that, compared to remaining in darkness, exposure to red light in the middle of the afternoon significantly improves alertness.

red-light_2725743Co-author Levent  Sahin, a doctoral student  at the Lighting Research Center, was interested in this study from a transportation safety perspective, and what the results could mean to the transportation industry. “Safety is a prerequisite and one of the most important quality indicators in the transportation industry,” said Sahin. “Our recent findings provided the scientifically valid underpinnings in approaching fatigue related safety problems in 24 hour transportation operations.”

Those of us who remember the lyrics of the 1978 Police hit Roxanne – “You don’t have to put on the red light,” may need to rethink…

Even though the present results don’t fully explain the underlying mechanisms of light-induced changes in alertness it seems we could all benefit from a little red light on our desks.

SRxA-logo for web

Lift Weights to Lower Blood Sugar?

Red-White_muscleSRxA’s Word on Health was interested to read that researchers in the Life Sciences Institute at the University of Michigan have overturned a long-held belief that whitening of skeletal muscle in diabetes is harmful.  Instead, they found that the white muscle that increases with resistance training, age and diabetes actually helps to keep blood sugar in check.

The insights identified in the study may point the way to potential drug targets for obesity and metabolic disease.

We wanted to figure out the relationship between muscle types and body metabolism, how the muscles were made, and also what kind of influence they have on diseases like type 2 diabetes,” said Jiandie Lin, Life Sciences Institute faculty member.

Much like poultry has light and dark meat, mammals have a range of muscles: red, white and those in between. Red muscle, which gets its color in part from mitochondria, prevails in people who engage in endurance training, such as marathon runners. White muscle dominates in the bodies of weightlifters and sprinters – people who require short, intense bursts of energy.

lifting-weightsWhen you exercise, nerves signal your muscles to contract, and the muscle needs energy. In response to a signal to lift a heavy weight, white muscles use glycogen to generate adenosine triphosphate (ATP) – energy the cells can use to complete the task. While this process can produce a lot of power for a short time, the glycogen fuel soon depletes.

However, if the brain tells the muscle to run a slow and steady long-distance race, the mitochondria in red muscles primarily use fat oxidation instead of glycogen breakdown to generate ATP. The supply of energy lasts much longer but doesn’t provide the burst of strength that comes from Paula_Radciffe_NYC_Marathon_2008_croppedglycolysis.

People with diabetes see whitening of the mix of muscle.

For a long time, the red-to-white shift was thought to make muscle less responsive to insulin, a hormone that lowers blood sugar,” Lin said. “But this idea is far from proven. You lose red muscle when you age or develop diabetes, but is that really the culprit?”

To find out, the team set out to find a protein that drives the formation of white muscle. They identified a list of candidate proteins that were prevalent in white muscle but not in red.

mouse weight liftingFurther studies led the team to focus on a protein called BAF60c, a sort of “zip code” mechanism that tells the cells when and how to express certain genes. The Lin team made a transgenic mouse model to increase BAF60c only in the skeletal muscle. One of the first things they noticed was that mice with more BAF60c had muscles that looked paler.

“That was a good hint that we were going in the white-muscle direction,” said lead author Zhuo-xian Meng, a research fellow in Lin’s lab.

They used electron microscopy to see the abundance of mitochondria within the muscle, and confirmed that muscle from BAF60c transgenic mice had less mitochondria than the normal controls.

We saw predicted changes in molecular markers, but the ultimate test would be seeing how the mouse could run,” Lin said.

treadmill mouseIf the BAF60c mice could run powerfully for short distances but tired quickly, the scientists would be able to confirm that the BAF60c pathway was a key part of the creation of white muscle.

Using mouse treadmills, they compared the endurance of BAF60c mice to a control group of normal mice, and found that the BAF60c transgenic mice could only run about 60% of the time that the control group could before tiring.

“White muscle uses glycogen, and the transgenic mice depleted their muscles’ supplies of glycogen very quickly,” Lin said.

After some follow-up experiments to figure out exactly which molecules were controlled by BAF60c, Lin and his team were confident that they had identified major players responsible for promoting white muscle formation.

Now that they knew how to make more white muscle in animals, they wanted to determine whether white muscle was a deleterious or an adaptive characteristic of diabetes.

obese mouseThe team induced obesity in mice by feeding them a “Super Size Me” mouse diet. On a high-fat diet, a mouse will double its body weight in two to three months. They found that obese mice with BAF60c transgene were much better at controlling blood glucose.

The results are a bit of a surprise to many people,” Lin said. “It really points to the complexity in thinking about muscle metabolism and diabetes.”

In humans, resistance training promotes the growth of white muscle and helps in lowering blood glucose. If future studies in humans determine that the BAF60c pathway is indeed the way in which cells form white muscle and in turn optimize metabolic function, the finding could lead to researching the pathway as a drug target.

We know that this molecular pathway also works in human cells. The real challenge is to find a way to target these factors,” Lin said.

Until we know for sure SRxA’s Word on Health recommends a healthy mix of running and weight training.

SRxA-logo for web

Stopping Herpes From Going Viral

herpes-simplex-virusOn Wednesday SRxA’s Word on Health reported on a link between memory loss and cognitive decline and the herpes virus.  Today, we bring a glimmer of hope to the 65% – 90% of people worldwide affected with either type 1 or Type 2 herpes simplex virus.

In the US alone, it’s estimated that nearly 60 percent of U.S. men and women between the ages of 14 and 49 carry the HSV-1 virus, while >16.2% are infected with herpes simplex virus type 2 (HSV-2).

HSV-2 is a lifelong and incurable infection that can cause recurrent and painful genital sores and can make those infected with the virus two-to-three times more likely to acquire HIV.

Now, according to a study just published in the Journal of the Federation of American Societies for Experimental Biology (FASEB), researchers from Albert Einstein College of Medicine of Yeshiva University have discovered a novel strategy for preventing, treating or suppressing herpes virus infections.

molecule_key_chains-We’ve essentially identified the molecular “key” that herpes viruses use to penetrate cell membranes and infect cells of the human body,” said Betsy Herold, MD of The Children’s Hospital at Montefiore.

Dr. Herold and her colleagues had previously shown that infection by the herpes viruses depends on calcium released within the cells. In this study, they found that calcium release occurs because the viruses activate a critical cell-signaling molecule called Akt [also known as Protein Kinase B (PKB) ] at the cell membrane.

As part of their investigation of Akt’s role in herpes infections, the researchers took laboratory cultures of human cell and mixed them for 15 minutes with four different drugs known to inhibit Akt. The cells were then exposed for one hour to herpes simplex virus 2.

The drugs tested were:

  • MK-2206 – an experimental drug being studied as adjunct therapy for cancer
  • Akt Inhibitor VIII
  • Miltefosine, a drug licensed for treatment of leishmaniasis and other protozoal infections
  • Perifosine, an experimental agent in phase 3 clinical trials for treatment of several cancers

STOPAll four of the drugs significantly inhibited HSV infection in each of the cell types.  Miltefosine was the most potent and reduced viral plaques by 90% in all cell types.

By contrast, cells not pre-treated with the Akt inhibitors were readily infected on exposure to the virus.

For people infected with herpes, the drug acyclovir helps prevent herpes outbreaks from recurring and lowers the risk of transmitting the infection to others,” said Dr. Herold. “But some people have herpes infections that don’t respond to acyclovir, and unfortunately there is no effective vaccine. So new approaches for suppressing and treating herpes infections are badly needed, and our findings indicate that inhibiting Akt should be a useful therapeutic strategy to pursue.”

SRxA-logo for web

Potential treatment for Ebola and other deadly viruses revealed

Ebola virusIllnesses caused by many of the world’s most deadly viruses cannot be effectively treated with existing drugs or vaccines. But this may all be about to change. Scientists have discovered several compounds that can inhibit the highly lethal Ebola virus, as well as the pathogens responsible for rabies, mumps, measles and other pathogenic viruses.

This finding, published in the journal Chemistry & Biology potentially opens up new therapeutic avenues for combating these diseases.

ebola-patientSuch treatments are desperately needed. Ebola virus, for example, can be transmitted through direct contact with blood or other body fluids of infected persons or animals, and even close contact with a deceased Ebola-infected body. And mortality rates from ebola can be as high as 90%.

The medical field currently does not have ideal antiviral therapies, often no therapeutics at all, and the development of broad-spectrum antivirals is a great way to provide treatment in the future,” says study author Claire Marie Filone PhD of Boston University School of Medicine. “Toward that end, we have identified a drug that targets multiple viruses – and may be developed into an antiviral treatment for known and emerging viruses.”

In contrast to the many antibiotics that work against a wide range of bacteria, there are currently no highly effective or safe broad-spectrum drug treatments for viral diseases.

virus cycleTo address this need, researchers screened thousands of diverse compounds for small molecules that showed strong antiviral activity against viruses.  They identified several that inhibited infection in cells exposed to either Ebola or vesicular stomatitis virus (VSV). These molecules, which are related to a class of plant-derived compounds called indoline alkaloids, share a common chemical structure that can be modified to enhance antiviral activity.

The most potent of these compounds demonstrated a consistent mechanism of action against genetically distinct viruses. It works by blocking viral transcription. Because it targets such a critical step in virus replication, in theory, scientists should be able to develop it into a therapeutic that could be used against many different types of viral infections.

As always, SRxA’s Word on Health will bring you further news as it develops.

SRxA-logo for web

Tee-Total but Drinking Yourself to Death?

Bloomberg Moves To Ban Sugary Drinks In NYC Restaurants And Movie TheatersAccording to research presented at the American Heart Association’s Epidemiology and Prevention/Nutrition, Physical Activity and Metabolism meeting last week, sugar-sweetened sodas, sports drinks and fruit drinks may be associated with a staggering 180,000 deaths around the world each year,

Researchers calculated the quantities of sugar-sweetened beverage intake around the world by age and sex.  They also looked at the effects of this on obesity and diabetes. Using data from the 2010 Global Burden of Diseases Study, they linked intake of sweetened beverages to 133,000 diabetes deaths, 44,000 cardiovascular disease deaths and 6,000 cancer deaths.

78% of these deaths were in low and middle-income countries.  But that doesn’t mean America is off the hook.

In the U.S., our research shows that about 25,000 deaths in 2010 were linked to drinking sugar-sweetened beverages,” said Gitanjali M. Singh, PhD, co-author of the study.

Of nine world regions in 2010:

  • Latin America/Caribbean had the most diabetes deaths (38,000) related to sugar-sweetened beverages
  • East/Central Eurasia had the largest numbers of cardiovascular deaths (11,000) related to sugary beverage consumption

Cola can and measuring tapeAmong the world’s 15 most populous countries, Mexico had the highest death rate due to these beverages, with 318 deaths per million adults.

Japan, one of the countries with lowest per-capita consumption of sugary beverages in the world, had the lowest death rate associated with the consumption of sugary beverages, at about 10 deaths per million adults.

Because we were focused on deaths due to chronic diseases, our study focused on adults. Future research should assess the amount of sugary beverage consumption in children across the world and how this affects their current and future health,” Singh said.

In the meantime, the American Heart Association recommends adults consume no more than 450 calories per week, from sugar-sweetened beverages.

diet soda 2And don’t assume you’re OK just because you drink diet, rather than regular soda. According to research presented at the American Stroke Association’s International Stroke Conference in  2011, drinking diet soda daily is linked to a higher risk of stroke, heart attack and vascular-related deaths, compared to those who don’t drink soda.  Even though you are avoiding the sugar calories, the high salt content may double the risk of ischemic stroke, independent of sodium’s role in hypertension.

Here at SRxA’s Word on Health we’re canning the cans and from now on it will be water all the way!

SRxA-logo for web

Parkinson’s Disease Therapy May Cause More Harm Than Good

parkinsons 1In a surprise finding, a study by researchers from NorthShore University HealthSystem and the Mayo Clinic provides genetic and clinical evidence that some new Parkinson’s disease therapies may actually accelerate disease progression and increase the risk of becoming physically incapacitated and demented.

Specifically problematic are those therapies that target the expression of alpha-synuclein – a protein whose function in the healthy brain is unknown, but is a major constituent of Lewy bodies, protein clumps that are the pathological hallmark of Parkinson’s disease.

AlphaSynuclein3Since its discovery as a cause of familial Parkinson’s disease nearly 20 years ago, alpha-synuclein has been the focus of intensive efforts by researchers working to definitively characterize the protein’s role in idiopathic Parkinson’s disease and its potential as a target for neuroprotective therapies.

This news is particularly concerning given that a vaccine targeting alpha-synuclein in Parkinson’s patients is currently undergoing clinical testing in Parkinson’s patients and a number of molecules that target the protein for reduction are in advanced stages of preclinical development.  The vaccine candidate, from Austrian biotech AFFiRiS, works by binding to alpha-synuclein and subsequently clearing it from the brain.

parkinsons-diseaseAs of January 2012, The Michael J. Fox Foundation had invested over $47 million in projects targeting alpha-synuclein.

Our research suggests that therapies that seek to suppress alpha-synuclein in Parkinson’s disease may actually accelerate the disease process and increase the risk for developing severe physical disability and dementia,” said lead author Demetrius M. Maraganore, MD. “We believe it is our responsibility to release these data because this type of treatment may have long-term harmful effects.”

For the first time, we observed that, while over-expression of alpha-synuclein increases the risk for developing Parkinson’s disease, conversely, under-expression is associated with worse motor and cognitive outcomes after the disease starts,” adds study author Katerina Markopoulou, MD, PhD, a neurologist at NorthShore.

The researchers followed 1,098 Mayo Clinic patients for nearly 15 years  and sequenced the patients’ DNA to determine the presence of gene variants that regulate how much alpha-synuclein protein is made. They also studied the association of these gene variants with patients’ survival free of severe motor and cognitive disabilities.

Patients who had reduced expression of alpha-synuclein had a 23% greater risk of becoming wheelchair-dependent or developing dementia.

If replicated, the findings, presented Wednesday at the annual meeting of the American Academy of Neurology will have profound implications regarding therapies under development for Parkinson’s disease.

hands_ParkinsonsInterestingly, this is not the first time alpha-synuclein has been challenged. SRxA’s Word on Health has discovered literature from 2008 showing that there are people with Parkinson’s Disease that have no accumulation of alpha-synuclein, and people who have accumulated alph-synuclein who do not have Parkinson’s Disease. In autopsy studies, 30%-55% of elderly subjects with widespread alpha-synuclein pathology were found to have no definite neuropsychiatric symptoms; yet when large amounts of alpha-synuclein had fewer patients were found to have Parkinson’s Disease.  These authors concluded that much of the Parkinson’s Disease research was being done without having any scientific or factual basis.

Looks like  people should have listened!

SRxA-logo for web

When’s Your Time to Die?

risk of dyingWhat are your chances of dying in the next 10 years?

Obviously there are some activities that may increase your risk  such as driving drunk and active military duty in a war zone, but how about getting winded after walking several blocks or having trouble pushing a chair across the room

Turns out the latter might be just as dangerous as the former.

Researchers at the University of San Francisco VA Medical Center have recently come up with a “mortality index” to predict when a person may die.  Marisa Cruz and her colleagues have developed a list of 12 questions that can help predict chances of dying within 10 years for patients aged 50 and older.  The researchers created the index by analyzing data on almost 20,000 Americans over 50 who took part in a national health survey in 1998. They tracked the participants for 10 years. Nearly 6,000 participants died during that time.

risk of dying 2While the test scores may satisfy people’s morbid curiosity, the researchers say their index wasn’t meant as guidance about how to alter your lifestyle.  Instead, it is mostly for use by doctors, to help them discuss the pros and cons of costly health screenings or medical procedures in patients who are unlikely to live 10 more years.

That said, we know that many of our readers are “simply dying” to take the test themselves – right now.

So without further ado…here’s how it works.

The 12 items on the mortality index are assigned points.  The fewer your total points the better odds of living.

  • Men automatically get 2 points. In addition, men and women ages 60 to 64 get 1 point; ages 70 to 74 get 3 points; and 85 or over get 7 points.
  • Two points each for: a current or previous cancer diagnosis, excluding minor skin cancers; lung disease limiting activity or requiring oxygen; congestive cardiac failure; smoking within the past 2 weeks; difficulty bathing; difficulty managing money because of health or memory problem; difficulty walking several blocks.
  • One point each for: diabetes or high blood sugar; difficulty pushing large objects, such as a heavy chair; being thin or normal weight.


The highest, or worst, score is  26, which equates to  a 95% chance of dying within 10 years. To get that, you’d have to be a man at least 85 years old with all the above conditions.
healthy young womanFor a score of zero, which correlates to a 3% chance of dying within 10 years, you’d have to be a woman of “normal weight” younger than 60 without any of those infirmities.

While it’s hardly surprising that a sick, older person would have a much higher chance of dying than someone younger why would being overweight be less risky than being of normal weight or slim?  One possible reason is that thinness in older age could be a sign of illness.

Dr. Stephan Fihn, a health quality measurement specialist with Veterans Affairs health services in Seattle, said the index seems valid and “methodologically sound.”
However, he adds that it is probably most accurate for the oldest patients, who don’t need a scientific crystal ball to figure out their days are numbered.

For fans of SRxA’s Word on Health, I’m pleased to report that my 10-year mortality index is zero. Let the blogging continue!

SRxA-logo for web